Evaluate Safety/Tolerability Intra-Arterial Temozolomide in Patients w/Extremity Melanoma by Isolated Limb Infusion
Status:
Completed
Trial end date:
2014-06-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine the safety profile of intra-arterial temozolomide
administration during Isolated Limb Infusion (ILI) by defining the dose limiting toxicities
associated with this treatment. This study also aims to determine the maximum tolerated dose
of intra-arterial administration of temozolomide during ILI that will be used in a phase II
trial.
Phase:
Phase 1
Details
Lead Sponsor:
Douglas Tyler
Collaborators:
Duke University H. Lee Moffitt Cancer Center and Research Institute M.D. Anderson Cancer Center Merck Sharp & Dohme Corp.